Gateway Investment Advisers LLC Grows Holdings in Johnson & Johnson (NYSE:JNJ)

Gateway Investment Advisers LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 564,807 shares of the company's stock after buying an additional 44,614 shares during the quarter. Johnson & Johnson accounts for about 1.1% of Gateway Investment Advisers LLC's investment portfolio, making the stock its 19th largest position. Gateway Investment Advisers LLC's holdings in Johnson & Johnson were worth $93,668,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Lantz Financial LLC lifted its holdings in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after purchasing an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $453,000. Horan Securities Inc. lifted its stake in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after buying an additional 90 shares in the last quarter. Strategic Financial Concepts LLC boosted its holdings in Johnson & Johnson by 57.9% in the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after buying an additional 1,271 shares during the period. Finally, State of Wyoming increased its stake in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after buying an additional 10,279 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.1%

NYSE JNJ traded up $0.16 during trading hours on Monday, hitting $155.19. 5,318,668 shares of the company were exchanged, compared to its average volume of 7,939,526. The stock has a market cap of $373.40 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a 50-day moving average price of $153.59 and a 200 day moving average price of $153.67. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.35%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent analyst reports. Raymond James dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.